Institute of Medicine

Pfizer acquires Redvax

Tuesday, January 6, 2015

Pfizer has acquired a controlling interest in Redvax, a spinoff from Redbiotec, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

[Read More]

Boston Children’s Hospital partners on pharmacogenomics study in pediatric population

Wednesday, February 5, 2014

Aiming to reduce adverse drug reactions—which affect some 70,000 children annually in the U.S.—a study at Boston Children’s Hospital, in partnership with the Medical College of Wisconsin(MCW) and the Children’s Hospital of Wisconsin Research Institute, is using genetic information to predict children’s reactions to medications, ultimately enabling clinicians to select a more individualized therapy for the patient.

[Read More]

IOM report identifies ways to further improve pediatric studies

Friday, March 2, 2012

Federal laws that motivate or require drug and biologic developers to conduct pediatric studies have yielded beneficial information to guide the use of medications in children, according to a new report by the Institute of Medicine (IOM).  Still, studies involving children continue to be limited, especially in certain areas such as medication use in newborns and long-term safety and effectiveness in children. 

[Read More]